| Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis GA Piazza, ALK Rahm, M Krutzsch, G Sperl, NS Paranka, PH Gross, ... Cancer research 55 (14), 3110-3116, 1995 | 598 | 1995 |
| Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle … GA Piazza, AK Rahm, TS Finn, BH Fryer, H Li, AL Stoumen, R Pamukcu, ... Cancer research 57 (12), 2452-2459, 1997 | 457 | 1997 |
| Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels GA Piazza, DS Alberts, LJ Hixson, NS Paranka, H Li, T Finn, C Bogert, ... Cancer research 57 (14), 2909-2915, 1997 | 427 | 1997 |
| Exisulind induction of apoptosis involves guanosine 3′, 5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin WJ Thompson, GA Piazza, H Li, L Liu, J Fetter, B Zhu, G Sperl, D Ahnen, ... Cancer research 60 (13), 3338-3342, 2000 | 373 | 2000 |
| Sulfone metabolite of sulindac inhibits mammary carcinogenesis HJ Thompson, C Jiang, J Lu, RG Mehta, GA Piazza, NS Paranka, ... Cancer research 57 (2), 267-271, 1997 | 305 | 1997 |
| Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines JTE Lim, GA Piazza, EKH Han, TM Delohery, H Li, TS Finn, R Buttyan, ... Biochemical pharmacology 58 (7), 1097-1107, 1999 | 266 | 1999 |
| Honokiol: a novel natural agent for cancer prevention and therapy S Arora, S Singh, GA Piazza, CM Contreras, J Panyam, AP Singh Current molecular medicine 12 (10), 1244-1252, 2012 | 232 | 2012 |
| NSAIDs inhibit tumorigenesis, but how? E Gurpinar, WE Grizzle, GA Piazza Clinical cancer research 20 (5), 1104-1113, 2014 | 224 | 2014 |
| The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment AM Fajardo, GA Piazza, HN Tinsley Cancers 6 (1), 436-458, 2014 | 217 | 2014 |
| Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway W Lu, C Lin, MJ Roberts, WR Waud, GA Piazza, Y Li PloS one 6 (12), e29290, 2011 | 214 | 2011 |
| An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB-and hypoxia-inducible … S Arora, A Bhardwaj, S Singh, SK Srivastava, S McClellan, CS Nirodi, ... Journal of Biological Chemistry 288 (29), 21197-21207, 2013 | 205 | 2013 |
| Cyclic GMP Mediates Apoptosis Induced by Sulindac Derivatives via Activation of c-Jun NH2-Terminal Kinase 1 JW Soh, Y Mao, MG Kim, R Pamukcu, H Li, GA Piazza, WJ Thompson, ... Clinical cancer research 6 (10), 4136-4141, 2000 | 177 | 2000 |
| Hypoxia-regulated microRNAs in human cancer G Shen, X Li, Y Jia, GA Piazza, Y Xi Acta Pharmacologica Sinica 34 (3), 336-341, 2013 | 169 | 2013 |
| MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit X Li, J Zhang, L Gao, S McClellan, MA Finan, TW Butler, LB Owen, ... Cell Death & Differentiation 19 (3), 378-386, 2012 | 151 | 2012 |
| Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis GA Piazza, WJ Thompson, R Pamukcu, HW Alila, CM Whitehead, L Liu, ... Cancer research 61 (10), 3961-3968, 2001 | 151 | 2001 |
| Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis ET Goluboff, A Shabsigh, JA Saidi, IB Weinstein, N Mitra, D Heitjan, ... Urology 53 (2), 440-445, 1999 | 151 | 1999 |
| COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs E Gurpinar, WE Grizzle, GA Piazza Frontiers in oncology 3, 181, 2013 | 145 | 2013 |
| Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation W Lu, HN Tinsley, A Keeton, Z Qu, GA Piazza, Y Li European journal of pharmacology 602 (1), 8-14, 2009 | 145 | 2009 |
| Sulindac metabolites induce caspase-and proteasome-dependent degradation of β-catenin protein in human colon cancer cells PL Rice, J Kelloff, H Sullivan, LJ Driggers, KS Beard, S Kuwada, G Piazza, ... Molecular cancer therapeutics 2 (9), 885-892, 2003 | 137 | 2003 |
| Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling N Li, Y Xi, HN Tinsley, E Gurpinar, BD Gary, B Zhu, Y Li, X Chen, ... Molecular cancer therapeutics 12 (9), 1848-1859, 2013 | 132 | 2013 |
